Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC)
Stock analysis · BME · Healthcare · Drug Manufacturers - Specialty & Generic
Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC) is a publicly traded company in the Healthcare sector. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →Earnings
Proprietary Signals
About Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical company that focuses on researching, developing, manufacturing, and commercializing medicinal products. Its operations span Spain, the European Union, OECD nations, and global markets. The company also markets certain products under license from other manufacturers. Its primary pharmaceutical portfolio includes Hibor and Enoxaparin biosimilar Becat, both low-molecular-weight heparins for preventing and treating venous thromboembolic conditions. Neparvis targets symptomatic chronic heart failure with reduced ejection in adult patients. For managing hypercholesterolemia, Rovi offers Absorcol, Vytorin, and Orvatez. Respiratory diseases like chronic obstructive pulmonary disease are treated with long-acting bronchodilators Hirobriz Breezhaler and Ulunar Breezhaler. Volutsa is available for men with benign prostatic hyperplasia (BPH) experiencing moderate to severe storage and voiding symptoms who have not adequately responded to monotherapy. Additionally, Medikinet and Medicebrán are used for attention deficit hyperactivity disorder (ADHD) in pediatric and adolescent patients. Beyond pharmaceuticals, Rovi provides various hospi…
Peers
Recent News
- No recent news available.
Related
Browse more tickers: sitemap